This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.
CAH vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Cardinal (CAH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Varian (VAR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q3.
The Zacks Analyst Blog Highlights: Newmont, Pool, Cardinal Health and American Water Works
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Newmont, Pool, Cardinal Health and American Water Works
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from gradual recovery in Clear Aligner shipment volumes in Q3.
4 Dividend Hikers to Bet On Amid Prolonged Uncertainty
by Shuvra Shankar Dey
Although it is rare to see firms raising dividends this year, Newmont Corporation (NEM), Pool Corporation (POOL), Cardinal Health (CAH) and American Water Works (AWK) have come up as exceptions.
Top Ranked Income Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 16th.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings
by Sriparna Ghosal
These three MedTech stocks are expected to grow post their Q3 earnings release.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Cardinal (CAH) Down 6.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.
Cardinal Health (CAH) Tops Q4 Earnings Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 14.29% and -0.99%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in Medical segment.
Earnings Preview: Cardinal Health (CAH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top Dividend Stocks to Maximize Your Retirement Income - July 13, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - July 07, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $51.68 in the latest trading session, marking a -0.98% move from the prior day.
Monmouth Assets Witness Solid Occupancy & Rent Collections
by Zacks Equity Research
Monmouth (MNR) witnesses solid occupancy and rent-collection numbers amid coronavirus pandemic and related uncertainties.